2C-E

Austria does not need to name 2C-E individually for the NPSV control to apply. The current NPSV defines Neue Psychoaktive Substanzen to include every substance covered by an Anlage II chemical definition, and Anlage II Z 2 covers every compound derivable from a phenethylamine basic structure, including substituted compounds. PubChem's current NCBI record identifies 2C-E as 2-(4-ethyl-2,5-dimethoxyphenyl)ethanamine / 2,5-dimethoxy-4-ethylphenethylamine, which is a substituted phenethylamine and therefore falls within Z 2. The 2024 replacement of Anlagen II and III entered into force at the end of 18 April 2024 (BGBl. II Nr. 106/2024); the cited RIS consolidation is current as of 27 August 2026. NPSG § 2 excludes substances lawfully placed on the market under applicable medicinal, pharmacy or medicinal-goods-import rules and separately excludes substances subject to the Suchtmittelgesetz; this dossier does not make an independent SMG classification or medicinal-law authorization finding. For the NPSG offense, § 4(1) requires intent to obtain an advantage plus intent that another person use the substance for a psychoactive effect; it is not a blanket claim that every private act of possession is a § 4 offense. Nevertheless, § 5 permits seizure/forfeiture and treats the substance as an object whose possession is generally prohibited unless a lawful use is credibly shown. Customs may secure suspected NPS shipments under § 7.

Denmark's current euphoriants order expressly lists 2C-E by its exact chemical name as List B item 89. List B substances may only be used for medical or scientific purposes. Under the order, handling must comply with the order; receipt and possession are limited to prescription/requisition holders, specified scientific or clinical laboratories and institutions, pharmacies, and Lægemiddelstyrelsen-authorized persons or businesses. List B import requires Lægemiddelstyrelsen authorization and a shipment-specific import certificate, and manufacture requires authorization. Unauthorized handling is prohibited and violations are punished under the Euphoriants Act, ordinarily by a fine or imprisonment up to two years; the 2025 amendment (effective 1 July 2025) adds the substance's dangerousness to sentencing factors. The current order took effect 29 March 2026 and repealed the 2021 order. The order's general definition also covers possible salts and simple derivatives with euphoriant effect; this dossier does not infer any broader analogue rule beyond that text.

The existing claim that 2C-E is controlled under the Schedule 3/Class C analogue catch-all is supported, but the exact substance identity and statutory qualification must not be conflated with the separately listed alpha-methyl compound DOET. Section 2(1) defines a controlled drug analogue as a substance having a structure substantially similar to that of any controlled drug, while excluding substances already specified in Schedules 1 or 2 or Parts 1-6 of Schedule 3, pharmacy-only/prescription/restricted medicines, approved Psychoactive Substances Act products, and non-psychoactive THC analogues. Schedule 3 Part 7 expressly describes amphetamine analogues with the 1-amino-2-phenylethane nucleus and substituted alkyl/alkoxy ring radicals; on the PubChem identity, 2C-E matches that structural description. Section 29C provides a defence to a possession charge if the defendant proves possession for a purpose other than consumption or supply, or supply/administration under a Director-General of Health-approved procedure. For ordinary Class C possession/use, the New Zealand Police statutory summary gives a maximum of 3 months' imprisonment and/or a $500 fine; Class C supply or manufacture is up to 8 years on indictment (or 1 year and/or $1,000 summarily), subject to charge and facts. The analogue wording uses a substantial-similarity/structural test rather than naming 2C-E, so a laboratory-confirmed identity and legal interpretation remain material; no claim is made for an unknown mixture, derivative, salt, medicine or approved product. The 2026 order (Gazette notice 2026-sl622) was checked for later named additions and does not displace the existing analogue rule.

The existing Portugal note is corrected: the Law n.º 30/2000 personal-use contraordenação regime is expressly limited to plants, substances and preparations in Tables I-IV of Decree-Law n.º 15/93, and the separate Decreto-Lei n.º 54/2013 NPS regime is limited to substances on the ministerial list (including their derivatives, isomers and salts). Neither current list names 2C-E or 2,5-dimetoxi-4-etilfenetilamina. Accordingly, the 10-day personal-use rule, referral to a dissuasion commission and the Article 21 trafficking/production offences are not direct 2C-E rules while this exact substance remains absent from the named lists. For listed substances, current Article 40(2)-(4) makes acquisition/detention for own consumption a contraordenação, treats more than the 10-day average as an indication rather than an automatic trafficking finding, and requires archiving, non-indictment or acquittal with referral when exclusive own use is proved; Article 21(1) provides 4-12 years for unauthorised listed-table I-III trafficking and other activities. The absence finding is limited to the exact identified free base: a sample containing another listed substance, a structural derivative/isomer/salt, or a differently identified compound requires separate analysis.

Freshly verified against the current Federal Register instrument, which is in force and commenced 1 June 2026. The bounded claim preserves the instrument's implementation caveat and approval exceptions and does not convert the federal scheduling recommendation into an unqualified nationwide prohibition. The current Customs (Prohibited Imports) Regulations compilation separately identifies 2C-E as 2,5-dimethoxy-4-ethylphenethylamine (otherwise known as 2C-E) in Schedule 4, item 66AA.

Current official sources support prohibited status, not the former uncited date-only note. The current Anvisa controlled-substances page identifies Portaria 344/98 as the controlling instrument, says its annex is updated periodically, and marks RDC nº 1.036 of 9 July 2026 as the current version in its update history; the page was modified 13 July 2026. The consolidated Portaria expressly identifies the compound and its chemical identity in F2 item 9. Portaria Article 2 requires Special Authorization for activities involving substances in the annexes, while Article 4 supplies the direct proscription rule. F2 Adendo 16 names 2C-E among analytical-standard substances eligible for a limited no-authorization import/export treatment at no more than 500 mg per unit; that exception is not a general consumer or research-use exemption. Lei 11.343 Article 1, sole paragraph, and Article 66 bring Portaria-controlled psychotropic substances into the statutory definition of drugs. Article 2 prohibits drugs nationwide and unauthorized planting/cultivation/harvesting/exploitation of drug-producing plants or substrates; Article 28 addresses unauthorized personal acquisition, keeping, deposit, transport or carrying with warning, community-service and educational measures (and does not legalize the conduct). Article 31 requires prior licensing for listed drug activities. Article 33 imposes 5–15 years' imprisonment and 500–1,500 day-fines for unauthorized import, export, preparation, production, manufacture, acquisition, sale, offering, storage, transport, possession, delivery or supply. The statutory provisions are scope and penalty rules; they do not create a 2C-E prescription or recreational market.

2C-E is expressly listed by exact chemical identity in the current non-medical narcotic/psychotropic catalog, not as a prescription medicine. The 2025 catalog consolidated and replaced the prior non-medical supplemental catalog, retained its 231 substances (including 2C-E), and expressly no longer distinguishes Category I versus Category II psychotropics in this catalog. Under current Regulation Article 4, non-medical listed substances may be used for experimental research only in accordance with the Regulation and may not be produced, operated/sold, used, stored, or transported; the 2015 implementing measure additionally expressly prohibits production, buying/selling, transport, use, storage, and import/export, with exceptions for regulated research, testing standards/reference materials, and specified intermediates. The original 2015 listing took effect 2015-10-01; the current consolidated catalog was issued and took effect 2025-07-21. The cited texts state no personal-use quantity threshold or amount-based exception; this dossier does not infer one. The 2025 catalog note includes possible salts, stereoisomers, and their salts unless otherwise provided. Regulation Article 82 provides, for violations causing controlled substances to enter illicit channels and cause harm, criminal liability where constitutive, or otherwise a RMB 50,000–100,000 police fine plus confiscation (serious cases may add 2–5 times illegal proceeds and permit cancellation).

Finland's current consolidated consumer-market-banned psychoactive-substance annex expressly lists 2C-E by its exact chemical identity. The 1130/2014 framework entered into force on 20 December 2014; its current annex is the 25 June 2026 consolidation, with Decree 650/2026 entering into force on 10 July 2026, and 2C-E remains listed. The Narcotics Act defines this category as intoxicant-use substances potentially dangerous to health that have been notified for control (or are positional isomers of such a substance) and are neither medicines nor narcotics. The exact 2C-E listing therefore supports restricted_other, not an assertion that 2C-E is in the separate narcotics schedules. Section 5(2) prohibits manufacture, import into Finland, storage, offering for sale and transfer; it does not itself state a blanket possession-or-use prohibition. Sections 23b and 33a provide narrow research/industrial and low-misuse-risk preparation exceptions plus record/reporting duties. Intentional or grossly negligent violations are punishable under Criminal Code chapter 44 § 5a by a fine or imprisonment for up to one year, unless a more severe offence applies. No generic analogue rule is inferred beyond the statutory category definition; the exact-name listing is sufficient.

2C-E is expressly named in the consolidated First Schedule, rather than being inferred from an analogue or generic rule. The schedule distinguishes it from DOET, which is the separate alpha-methyl compound 4-ethyl-2,5-dimethoxy-alpha-methylphenethylamine. Under section 1, a dangerous drug includes every substance in the First Schedule and its salts, preparations, compounds, mixtures and solutions. Section 6 requires a Director's licence for cultivation, production, extraction, preparation or manufacture; section 7 prohibits unauthorized possession or use (up to 20 years' imprisonment or the statutory fine, and up to 3 years or the statutory fine for possession/use solely for personal consumption); section 13 prohibits unauthorized export, import, facilitating import/export, trade, other dealings and supply; and section 19a makes breach of the trade/import/export/supply provisions punishable by up to 20 years or the statutory fine. The 2025 Gazette amendment was inspected as the latest schedule amendment: it changes the chemical-group definition and adds other substances, but does not replace or remove item 7b. The Ordinance's authorization, licensed medical/research and transit exceptions remain material; no general adult possession, use or personal-use exception applies to 2C-E.

Turkey's 2015/7238 annex generically controls specified amphetamine (phenethylamine) derivatives under Law 2313 rather than requiring 2C-E to be individually named. The annex permits hydrogen at the side-chain and amine positions, methoxy at the R5 position, and alkyl/alkoxy substituents on the phenyl ring, matching 2C-E's structure. The decision is dated 26 January 2015 and was published in the Official Gazette on 6 February 2015 (the publication-effective date used here); UNODC records 2015 as the first-control year and describes the generic-law amendment as in force since January 2015. Law No. 6545 was published on 28 June 2014 and its Article 66 amendments to TCK Article 188 and Article 68 amendment to Article 191 took effect on publication. Law No. 7445 was published on 5 April 2023; its Article 17 amendment adding amphetamine derivatives to TCK Article 188(4)(a) also took effect on publication. Current TCK Article 188(1) provides 20–30 years' imprisonment and up to 20,000 days' judicial fine for unlicensed or unauthorized manufacture, import or export; Article 188(3) provides at least 10 years and up to 20,000 days' fine for domestic sale, offer, giving, transport, storage, purchase, acceptance or possession. Law No. 7445 Article 17 amended TCK Article 188(4)(a) to include amphetamine and derivatives among substances triggering a half increase, so the enhancement may apply when 2C-E is treated as the scheduled amphetamine/phenethylamine derivative (subject to the court's classification). Article 191(1), as amended by Law No. 6545, separately provides 2–5 years for purchase, acceptance, possession or use for personal consumption, with treatment/probation provisions in Article 191. The 10 January 2026 No. 33133/Decision 10851 update names 2C-EF (a distinct fluoroethyl analogue), not 2C-E, and does not repeal the 2015 generic phenethylamine category. This is a statutory classification; exact treatment of a seized sample, salt or formulation can require forensic identification and application of the then-operative text.